West Pharmaceutical Services (WST) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $128.2 million.
- West Pharmaceutical Services' Income towards Parent Company rose 7.81% to $128.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $479.3 million, marking a year-over-year increase of 27.2%. This contributed to the annual value of $479.3 million for FY2025, which is 27.2% up from last year.
- Latest data reveals that West Pharmaceutical Services reported Income towards Parent Company of $128.2 million as of Q4 2025, which was up 7.81% from $137.9 million recorded in Q3 2025.
- Over the past 5 years, West Pharmaceutical Services' Income towards Parent Company peaked at $183.0 million during Q2 2022, and registered a low of $86.4 million during Q1 2025.
- For the 5-year period, West Pharmaceutical Services' Income towards Parent Company averaged around $137.0 million, with its median value being $134.0 million (2023).
- In the last 5 years, West Pharmaceutical Services' Income towards Parent Company surged by 12075.72% in 2021 and then crashed by 3243.06% in 2022.
- Quarter analysis of 5 years shows West Pharmaceutical Services' Income towards Parent Company stood at $147.7 million in 2021, then crashed by 32.43% to $99.8 million in 2022, then skyrocketed by 33.97% to $133.7 million in 2023, then fell by 4.19% to $128.1 million in 2024, then increased by 0.08% to $128.2 million in 2025.
- Its Income towards Parent Company stands at $128.2 million for Q4 2025, versus $137.9 million for Q3 2025 and $126.8 million for Q2 2025.